E
Equillium, Inc. (EQ)
NCM – Real Time Price. Currency in USD
2.27
+0.02 (0.89%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.27
+0.02 (0.89%)
At close: May 12, 2026, 4:00 PM EDT
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Name | Position |
|---|---|
| Dr. Lisette Acevedo | Vice President of Clinical Development |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & President |
| Mr. Bruce D. Steel C.F.A. | Co-Founder, CEO & Director |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior VP & COO |
| Ms. Penny Tom CPA | Senior VP of Finance & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-15 | DEFA14A | eq-defa14a-2026.htm |
| 2026-04-15 | DEF 14A | eq-20260414.htm |
| 2026-04-07 | S-3 | d116924ds3.htm |
| 2026-03-30 | PRE 14A | eq-20260330.htm |
| 2026-03-25 | S-8 | d25194ds8.htm |
| 2026-03-13 | 8-K | d125584d8k.htm |
| 2025-11-13 | S-3 | d53133ds3.htm |
| 2025-11-13 | 8-K | eq-20251113.htm |
| 2025-10-24 | 8-K/A | eq-20250930.htm |
| 2025-10-06 | 8-K | d930780d8k.htm |